Bexagliflozin
- Generic Name
- Bexagliflozin
- Brand Names
- Brenzavvy
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29ClO7
- CAS Number
- 1118567-05-7
- Unique Ingredient Identifier
- EY00JF42FV
- Background
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity. In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.
- Indication
Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 164
- Registration Number
- NCT05612594
- Locations
- 🇺🇸
Yale New Haven Health, New Haven, Connecticut, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Theracos
- Target Recruit Count
- 16
- Registration Number
- NCT03557658
- Locations
- 🇺🇸
Clinical Research Site 2, Saint Paul, Minnesota, United States
🇺🇸Clinical Research Site 1, Boston, Massachusetts, United States
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Theracos
- Target Recruit Count
- 673
- Registration Number
- NCT03514641
- Locations
- 🇺🇸
Clinical Research Site, Tacoma, Washington, United States
🇺🇸Clinical Research Site 2, Anderson, South Carolina, United States
Absolute Bioavailability Study With Bexagliflozin
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Theracos
- Registration Number
- NCT03417076
- Locations
- 🇺🇸
Clinical Research Site, Madison, Wisconsin, United States
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Theracos
- Target Recruit Count
- 48
- Registration Number
- NCT03296800
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Theracos
- Target Recruit Count
- 351
- Registration Number
- NCT03259789
- Locations
- 🇺🇸
Clinical Research Site 1382, Norwalk, Connecticut, United States
🇺🇸Clinical Research Site 1373, Pembroke Pines, Florida, United States
🇺🇸Clinical Research Site 1366, Chicago, Illinois, United States
Bexagliflozin Drug/Drug Interaction Study With Digoxin
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Theracos
- Target Recruit Count
- 20
- Registration Number
- NCT03197324
- Locations
- 🇺🇸
Covance CRU, Daytona Beach, Florida, United States
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Theracos
- Target Recruit Count
- 20
- Registration Number
- NCT03167411
- Locations
- 🇺🇸
Clinical Research Site, Evansville, Indiana, United States
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Theracos
- Target Recruit Count
- 386
- Registration Number
- NCT03115112
- Locations
- 🇵🇱
Clinical Research Site 7138, Lublin, Poland
🇵🇱Clinical Research Site 7137, Gdańsk, Poland
🇵🇱Clinical Research Site 7141, Kraków, Poland
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Theracos
- Target Recruit Count
- 54
- Registration Number
- NCT02956044
- Locations
- 🇺🇸
Clinical Research Site, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.